Henry-Georges Lombart currently serves as a Consultant in Medicinal Chemistry at AsisChem, a leading contract research organization (CRO) specializing in drug discovery and development. With a robust background in medicinal and organic chemistry, Henry-Georges has been instrumental in designing and synthesizing innovative small-molecule inhibitors that...
Henry-Georges Lombart currently serves as a Consultant in Medicinal Chemistry at AsisChem, a leading contract research organization (CRO) specializing in drug discovery and development. With a robust background in medicinal and organic chemistry, Henry-Georges has been instrumental in designing and synthesizing innovative small-molecule inhibitors that play a pivotal role in advancing therapeutic candidates across various disease areas, including rheumatoid arthritis, diabetes, and asthma. His expertise in structure-based drug design allows him to leverage computational methods to optimize lead compounds, ensuring that they possess the desired pharmacological properties.
In his role at AsisChem, Henry-Georges is not only involved in the technical aspects of medicinal chemistry but also excels in project management, coordinating multidisciplinary teams to drive projects from conception through to preclinical development. His proficiency in parallel synthesis and high-performance liquid chromatography (HPLC) enables him to efficiently generate and analyze compound libraries, facilitating rapid lead optimization. Additionally, his knowledge of ADME (Absorption, Distribution, Metabolism, and Excretion) properties ensures that the compounds he develops are not only potent but also viable as drug candidates.
Henry-Georges’s extensive skill set encompasses heterocyclic chemistry, pharmacology, and analytical chemistry, allowing him to navigate the complexities of drug development with ease. His commitment to innovation and excellence in the field of medicinal chemistry positions him as a valuable asset to AsisChem and the broader pharmaceutical landscape, where he continues to contribute to the discovery of next-generation therapeutics.
